417 related articles for article (PubMed ID: 2121387)
1. Anti-CD3 monoclonal antibody induction therapy. Immunological equivalency with triple-drug therapy in heart transplantation.
Barr ML; Sanchez JA; Seche LA; Schulman LL; Smith CR; Rose EA
Circulation; 1990 Nov; 82(5 Suppl):IV291-4. PubMed ID: 2121387
[TBL] [Abstract][Full Text] [Related]
2. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients.
Prieto M; Lake KD; Pritzker MR; Jorgensen CR; Arom KV; Love KR; Emery RW
J Heart Lung Transplant; 1991; 10(6):901-11. PubMed ID: 1661608
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with Muromonab-CD3 monoclonal antibody (OKT3) in heart transplantation.
Macris MP; Frazier OH; Lammermeier D; Radovancevic B; Duncan JM
J Heart Transplant; 1989; 8(4):281-7. PubMed ID: 2504894
[TBL] [Abstract][Full Text] [Related]
4. OKT3 monoclonal antibody given for ten versus fourteen days as immunosuppressive prophylaxis in heart transplantation.
Hegewald MG; O'Connell JB; Renlund DG; Lee HR; Burton NA; Karwande SV; Jones KW; Lassetter JE; Bristow MR
J Heart Transplant; 1989; 8(4):303-9; discussion 309-10. PubMed ID: 2504897
[TBL] [Abstract][Full Text] [Related]
5. Selective use of OKT3 in heart transplantation with the use of risk factor analysis.
Macris MP; Van Buren CT; Sweeney MS; Frazier OH; Duncan JM
J Heart Transplant; 1989; 8(4):296-302. PubMed ID: 2504896
[TBL] [Abstract][Full Text] [Related]
6. Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study.
Ross HJ; Gullestad L; Pak J; Slauson S; Valantine HA; Hunt SA
J Heart Lung Transplant; 1997 Feb; 16(2):179-89. PubMed ID: 9059929
[TBL] [Abstract][Full Text] [Related]
7. Prospective randomized trial of OKT3- versus horse antithymocyte globulin-based immunosuppressive prophylaxis in heart transplantation.
Costanzo-Nordin MR; O'Sullivan EJ; Johnson MR; Winters GL; Pifarre R; Radvany R; Zucker MJ; Scanlon PJ; Robinson JA
J Heart Transplant; 1990; 9(3 Pt 2):306-15. PubMed ID: 2113094
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic therapy for rejection after cardiac transplantation. A comparison of rabbit antithymocyte globulin and OKT3.
Kirklin JK; Bourge RC; White-Williams C; Naftel DC; Thomas FT; Thomas JM; Phillips MG
J Thorac Cardiovasc Surg; 1990 Apr; 99(4):716-24. PubMed ID: 2108282
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic OKT3 used as induction therapy for heart transplantation.
Starnes VA; Oyer PE; Stinson EB; Dein JR; Shumway NE
Circulation; 1989 Nov; 80(5 Pt 2):III79-83. PubMed ID: 2509108
[TBL] [Abstract][Full Text] [Related]
10. OKT3 prophylaxis versus conventional drug therapy: single-center perspective, part of a multicenter trial.
Kahana L; Narvarte J; Ackermann J; LeFor W; Weinstein S; Wright C; deQuesada A; Baxter J; Shires D
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):5-9. PubMed ID: 2510510
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of heart transplant recipients treated with murine antihuman mature T cell monoclonal antibody (OKT3): the Loyola experience.
Costanzo-Nordin MR; O'Sullivan EJ; Hubbell EA; Zucker MJ; Pifarre R; McManus BM; Winters GL; Scanlon PJ; Robinson JA
J Heart Transplant; 1989; 8(4):288-95. PubMed ID: 2504895
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppression after heart transplantation: prednisone and cyclosporine with and without azathioprine.
Casale AS; Reitz BA; Greene PS; Augustine S; Baumgartner WA
J Thorac Cardiovasc Surg; 1989 Nov; 98(5 Pt 2):951-5. PubMed ID: 2811426
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
Schroeder TJ; First MR; Mansour ME; Alexander JW; Penn I
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):14-8. PubMed ID: 2510506
[TBL] [Abstract][Full Text] [Related]
14. Unique antithymocyte serum versus OKT3 for induction immunotherapy after heart transplantation.
Frist WH; Merrill WH; Eastburn TE; Atkinson JB; Stewart JR; Hammon JW; Bender JW
J Heart Transplant; 1990; 9(5):489-94. PubMed ID: 2121921
[TBL] [Abstract][Full Text] [Related]
15. Independent risk factors predicting acute graft rejection in cardiac transplant recipients treated by triple drug immunosuppression.
Laufer G; Miholic J; Laczkovics A; Wollenek G; Holzinger C; Hajek-Rosenmeier A; Wuzl G; Schreiner W; Buxbaum P; Wolner E
J Thorac Cardiovasc Surg; 1989 Dec; 98(6):1113-21. PubMed ID: 2586129
[TBL] [Abstract][Full Text] [Related]
16. Five-year follow-up of a randomized double-drug versus triple-drug therapy immunosuppressive trial after heart transplantation.
Keogh A; Macdonald P; Mundy J; Chang V; Harvison A; Spratt P
J Heart Lung Transplant; 1992; 11(3 Pt 1):550-5; discussion 556. PubMed ID: 1610863
[TBL] [Abstract][Full Text] [Related]
17. Selective OKT3 induction therapy in adult cadaveric-donor renal transplant recipients.
Thistlethwaite JR; Heffron TG; Stuart JK; Buckingham M; Stuart FP
Am J Kidney Dis; 1989 Nov; 14(5 Suppl 2):28-34. PubMed ID: 2510508
[TBL] [Abstract][Full Text] [Related]
18. Five-year experience with triple-drug immunosuppressive therapy in cardiac transplantation.
Olivari MT; Kubo SH; Braunlin EA; Bolman RM; Ring WS
Circulation; 1990 Nov; 82(5 Suppl):IV276-80. PubMed ID: 2225416
[TBL] [Abstract][Full Text] [Related]
19. A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3.
Renlund DG; O'Connell JB; Gilbert EM; Hammond ME; Burton NA; Jones KW; Karwande SV; Doty DB; Menlove RL; Herrick CM
Transplantation; 1989 Apr; 47(4):599-605. PubMed ID: 2523099
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic cytolytic therapy in heart transplantation: monoclonal versus polyclonal antibody therapy.
Laske A; Gallino A; Schneider J; Bauer EP; Carrel T; Pasic M; von Segesser LK; Turina MI
J Heart Lung Transplant; 1992; 11(3 Pt 1):557-63. PubMed ID: 1610864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
